u/anders_karlsen

Correction: that stability figure covers the lyophilised powder, not the reconstituted solution. Different claim entirely.

Correction: that is regulatory approval, not coverage. They are separate decisions by separate bodies.

area percent unless the report says otherwise

I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.

Disagree that the pace matters as much as you think. Durable is better than fast and nobody posts about durable.

The evidence standard on the vendor boards requires a document, a date or a named service behind any claim about a supplier. It is what makes those threads worth reading years later.

Correcting myself: I quoted net peptide content against somebody else’s area percent. Not a comparison.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

vendor, compound, batch, service, result — that is the template

Gel pack fully liquid on arrival, powder tested 97.7% against a claimed 97.5% afterwards. The pack had done its job for as long as it was designed to.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Agreed — the template exists because a result without the batch and the claim is unanchored.

nothing on this board is a substitute for someone who knows your history

Did the vial lot match the paperwork lot?

Have you seen the special authorization criteria for your province?

Push back: the ranking is not hiding anything. The formula is published and you can reproduce the ordering.

Body weight varies by a couple of kilos day to day through fluid, glycogen and gut content, which is why a single weigh-in is noise and a fortnightly trend is signal.

if you are going to test, test the thing you actually received

Right, and asking what the stability statement was written against is one line of email that reframes everything.

Feed position is a function of early votes and time. That structurally favours agreeable early answers over correct late ones, which is why sorting by controversial occasionally is worth the effort.

This. Waist measurement kept moving through my longest stall and it was the only thing that kept me sane.

A goal weight chosen before starting is a prediction made with the least information you will ever have. Revising it is ordinary rather than a failure.

Regional stock changes the question rather than answering it: shorter lanes mean less exposure and fewer variables, which is why the warehouse question is worth asking before ordering in summer.

vendor, compound, batch, service, result — that is the template

Went looking for trial data on the specific question asked here and found the population had not been enrolled.

Has your plan renewed since the last time you applied?

the timeframe matters as much as the number

a summer lane and a winter lane are different lanes

Daily dosing, so what does the exposure profile look like across the day?

Area percent and net peptide content are different measurements and most reports give one. Quote which, or the comparison downstream is meaningless.

Disagree with loosening that. The evidence rule is why a supplier report here means something.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

open-label extensions are not the same evidence as the randomised phase

Nothing on this board is medical advice, and rate, target and method are questions for somebody who knows your history.

Text-only posting removes the comparison mechanism that makes image boards difficult, which is why this community adopted the rule and has kept it.

Slight disagreement: that is a month, not a plateau, and calling it one makes it heavier than it is.

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

a non-peptide agonist does not degrade the way a peptide does

The first thing I noticed was a jacket doing up. The scale had been flat for three weeks at that point.